Orthocell (ASX:OCC) said it sold 100 units of its Remplir nerve repair product in the US, according to a Thursday Australian bourse filing.
This follows 61 active submissions to US hospital Value Analysis Committees, with 17 approvals secured ahead of schedule and additional approvals anticipated in fiscal 2026, the filing said. The first 4,000 units of Remplir have been shipped from Australia and warehoused in the US.
Orthocell's shares fell past 2% in recent trading on Thursday.